SCHEMBL5845003

SCHEMBL5845003

CS(=O)(=O)NCc1ccc(CC(=O)O)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.69
TSHR P16473 2/20 0.58
KDM4E B2RXH2 1/20 0.58
POLB P06746 1/20 0.58
RECQL P46063 1/20 0.58
CA2 P00918 2/20 0.48
CAMK2A Q9UQM7 1/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
MEP1B Q16820 1/20 0.47
AKR1B1 P15121 1/20 0.47
EPHX2 P34913 1/20 0.46
NR1H4 Q96RI1 1/20 0.46
OPRM1 P35372 1/20 0.46
OPRD1 P41143 1/20 0.46
OPRK1 P41145 1/20 0.46
FFAR1 O14842 1/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11109419 0.82 TBXA2R (0.60) KMT2ATSHRPOLBCA2CAMK2A
SCHEMBL5843449 0.82 KMT2A (0.60) KMT2ATSHRKDM4EPOLBRECQL
SCHEMBL2841195 0.81 KMT2A (1.00) KMT2ATSHRKDM4EPOLBRECQL
Hydrochloric Acid SCHEMBL3526720 0.80 KMT2A (0.96) KMT2ATSHRKDM4EPOLBRECQL
SCHEMBL5844585 0.80 POLB (0.68) KMT2ATSHRPOLBCA2CAMK2A
SCHEMBL23241443 0.79 KMT2A (0.53) KMT2ATSHRKDM4EPOLBRECQL
SCHEMBL20607584 0.79 KMT2A (0.65) KMT2ATSHRKDM4EPOLBRECQL
SCHEMBL5842215 0.79 CA2 (0.46) KMT2ATSHRKDM4EPOLBCA2
SCHEMBL7230378 0.79 KMT2A (0.65) KMT2ATSHRKDM4EPOLBRECQL
SCHEMBL3605085 0.79 KMT2A (0.65) KMT2ATSHRKDM4EPOLBRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107474024-B Glutaminase inhibitor and composition and application thereof 北京赛林泰医药技术有限公司 2022-12-13 CN disclosed
US-6992193-B2 Sulfonylamino phenylacetamide derivatives and methods of their use ADOLOR CORPORATION (US) 2006-01-31 US disclosed
WO-2005004796-A2 SULFONYLAMINO PHENYLACETAMIDE DERIVATIVES AND METHODS OF THEIR USE ADOLOR CORPORATION (US) 2005-01-20 WO disclosed
US-20040254156-A1 Sulfonylamino phenylacetamide derivatives and methods of their use CALIXA THERAPEUTICS, INC. 2004-12-16 US disclosed
US-4855314-A VASOCONTRICTORS, TREATMENT OF MIGRAINES, 3-(AMINO-ETHYL)-5-(PHENYL(ALKYL)-CARBONYL OR SULFONYL-AMINOALKYL SUBSTITUTED GLAXO GROUP LIMITED (GB) 1989-08-08 US disclosed
EP-0240096-A1 Indole derivatives having a selective vasoconstrictor activity GLAXO GROUP LIMITED (GB) 1987-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254156-A1 Sulfonylamino phenylacetamide derivatives and methods of their use CYP2E1, CYP2D6, CYP3A43 KMT2A 1728/4885TSHR 1479/4885KDM4E 2340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.